Aslan Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports
WSBF Waterstone Financial Inc
Go

Health Care : Biotechnology | Small Cap Value
Based in Singapore
Company profile

ASLAN Pharmaceuticals Limited is a clinical-stage oncology and immunology focused biopharmaceutical company. The Company’s portfolio is comprised of one monoclonal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology. The Company’s products include ASLAN004, ASLAN003 and Varlitinib. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN003 is an inhibitor of human dihydroorotate dehydrogenase (DHODH), in acute myeloid leukemia (AML) and are exploring development in other solid tumors. Varlitinib is an oral, reversible small-molecule pan-HER inhibitor.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$1.64
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
84,477
0

Exxon Mobil's stock falls after wider-than-expected loss, as oversupply and COVID-19 weighed on results

7:55 am ET July 31, 2020 (MarketWatch)
Print

Shares of Exxon Mobil Corp. (XOM) fell 1.0% in premarket trading Friday, after the oil giant reported a wider-than-expected second-quarter loss and revenue that fell more than forecast, as the global oversupply of oil and the COVID-19 pandemic drove down results. The company swung to a net loss of $1.08 billion, or 26 cents a share, from net income of $3.13 billion, or 73 cents a share, in the year-ago period. Excluding non-recurring items, such as a gain from inventory valuation adjustments resulting from rising commodity prices, the adjusted loss per share was 70 cents, compared with the FactSet loss consensus of 61 cents. Total revenue dropped 52.8% to $32.61 billion, below the FactSet consensus of $38.16 billion. Oil-equivalent production fell 7% to 3.6 million barrels per day, which was above the FactSet consensus of 3.4 million barrels per day, as liquids production fell 3% and natural gas decreased 12%. "The global pandemic and oversupply conditions significantly impacted our second quarter financial results with lower prices, margins, and sales volumes," said Chief Executive Darren Woods. The company said it doesn't plan to take on more debt, as it believes it has already increased debt to a level that is "appropriate" given current market uncertainties. The stock has tumbled 40.0% year to date through Thursday, while the SPDR Energy Select Sector ETF (XLE) has shed 39.7% and the Dow Jones Industrial Average has lost 7.8%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 31, 2020 07:55 ET (11:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.